New England and Old England are battered by storm, rain and snow; Vienna is calm and actually too warm for that time of the year, but we are battered by work.... which is good of course... but can play havoc with our schedules. - Well, but here are repurposing patent applications, all from for January 2014 with one interesting exception from December 2013. - Dear Readers, we would appreciate your...

Happy New Year 2014! - Here are comments on seven international drug repurposing patent applications, all published in December 2013. - CuresWithinReach, a U.S. medical research non-profit organization and a major driver in the repurposing field, has listed us right on top of their list of the Blogs we Like section of their blog, re:Rx. Thank you CWR, H.M. Pharma Consultancy is honored!https://www...

The response we keep getting from our drug repurposing information services is just amazing! We truly seem to have hit a nerve here. With new chemical entities constantly dropping out of clinical development and hardly any new mechanisms with superior potential, revisiting old drugs or discontinued candidate compounds, repurposing is more attractive than ever. - An although the news might not have...

So much output from the WIPO and so little time to review! - But here are some more applications published in September and early October 2013. Stay tuned!https://www.hmpharmacon.com| office@hmpharmacon.com| Bitmessage: BM-2DB4Z3ee6C9mbtKx92q56Xt1uT1YNBeiq9--------------------More on Antiangiogenic ItraconazoleThe antiangiogenic potential of the popular antifungal drug itraconazole(Sporanox®) was ...

Try "drug repurposing" with any web search engine and you will see that the concept of finding new applications for known drugs, drug candidates in clinical development, and investigational molecules that have failed their original application has become quite popular. Browse this blog and you will see that H.M. Pharma Consultancy routinely flags and briefly reviews several international patent ap...

One and a half years ago, this blog has already discussed some problematic aspects of making patient-level clinical trial data available to anybody beyond the segment that can see them today -- i.e., to parties other than the sponsor who pays for their generation, the statisticians analyzing them, and the regulatory authorities who base their decisions on them. Matters have taken their course sinc...

We are catching up on the backlog of drug repurposing patent commentaries; here we present five applications published in September and early October 2013.At H.M. Pharma Consultancy we are building a database covering peer review and patent literature on drug repurposing, a tool that is strictly internal at the moment but will become increasingly useful as the content grows. Much on this blog deal...

And a very good day to you, colleagues in drug repurposing! Shame on us for not posting for many weeks, but this kind of activity is contingent on free time slots - which were just not available for most of the time. Drug repurposing activities have not taken a break though. OK, here we go with five applications published in August.https://www.hmpharmacon.com| office@hmpharmacon.com| Bitmessage: B...

Is it just us, or are you too seeing more papers, and hearing more talk, about drug repurposing recently? For sure there are more international patent applications with this focus being published this summer, which is why we are pushing out another issue of or reviews barely a week after the last one.In five out of the six cases we present, it is the original developer who is claiming distinct new...

There has been no shortage of revelations concerning covert digital surveillance this summer, but H.M. Pharma Consultancy plows onward with its own surveillance program for drug repurposing -- which is entirely based on very public documents such as those five patent applications reviewed below. If you want to make use of our know-how in this promising space of life science developments, please co...